Promising data for AEterna Zentaris' AEZS-108

Canadian drugmaker AEterna Zentaris presented encouraging data from a Phase I trial of its targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog, AEZS-108, in female patients with cancers expressing LHRH receptors, at the American Society of Clinical Oncology's annual meeting, in Chicago.

Out of those on 160mg/m2 or 267mg/m2 doses of the agent, seven of 13 patients showed signs of tumor response, including three with complete or partial responses.

David Mazzo, AEterna Zentaris chief executive noted that "the outcome of this study with AEZS-108 is very encouraging as we are preparing to initiate our Phase II trial in endometrial and ovarian cancers. We believe that our targeted approach, including only patients with LHRH receptor expressing tumors, is the key to both individual patient safety and clinical benefit as well as the potential success of the upcoming trial."